By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

Pfizer beat Wall Street expectations for first-quarter 2026 revenue and profit, driven by strong sales of newer and acquired medicines. The company reaffirmed its full-year guidance and said a ...

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...

Anchored by TV spots and sports media placements, the Every Inch Matters campaign positions the projected number one overall ...